Organogenesis Holdings Inc.

NASDAQ:ORGO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.85 +3.21%

+$0.08 today

Market cap
$110.75M
Beta
1.33
P/E (TTM)
-1086.7
EPS (TTM)
-$0.00
52W Low $2.04High $7.08

Volume 0.86M

Average 1.49M

ORGO Total Current Assets

All assets expected to be converted to cash or used up within one year.

Organogenesis Holdings Inc.NASDAQ: ORGO

Total Current Assets · Q1 FY2026 · quarter ended Mar 2026

Total current assets broadly unchanged from a year ago

Total current assets stood at $268.5M at the end of Q1 FY2026, up 0.1% from a year earlier and down 25.9% from the prior quarter. Over 3 fiscal years it compounded at +17.6% a year.

Context

  • Total current assets amounted to 51.6% of total assets at the end of Q1 FY2026, down 5.7 pp from a year earlier.
  • Total current assets increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total current assets keeps rising in the next quarterly balance sheet after a +0.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$268.5M-25.9% QoQ
Last fiscal yearDec 2025
$362.19M+26.7% YoY
Year agoMar 2025
$268.16M+0.1% since
Total Current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.1%——
1 year+26.7%——
3-year CAGR+17.6%——
5-year CAGR——
10-year CAGR——

Total Current Assets history

USD · from the balance sheet

Latest · FY2025
362.19M USD
Year-over-year change
+26.7%
4-year CAGR
+12.4%

Total Current Assets vs competitors

How ORGO compares with its peers on the latest reported figures

  • Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +0.1% is the 5th highest of 11, against a peer median of -4.4%.
  • Total current assets amounts to 51.6% of total assets for ORGO, versus a peer median of 78.9%.
ORGO Competitors
Total Current Assets for ORGO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
EBSEmergent BioSolutions Inc.Mar 2026$637.6M USD-9.8%-18.2%48.3%
VREXVarex Imaging CorporationApr 2026$625.6M USD-8.5%+1.7%57.4%
BCYCBicycle Therapeutics plcMar 2026$619.14M USD-27.7%+19.4%94.9%
ESPREsperion Therapeutics, Inc.Mar 2026$459.46M USD+44.1%+23.3%99.3%
SNDLSNDL Inc.Mar 2026CA$419.53M CAD-0.3%-3.5%31.9%
ORGOOrganogenesis Holdings Inc.Mar 2026$268.5M USD+0.1%+17.6%51.6%
SIGASIGA Technologies, Inc.Mar 2026$211.53M USD-9.5%+4.6%96.4%
CMPXCompass Therapeutics, Inc.Mar 2026$195.69M USD+57.6%+2.5%95.4%
ANGOAngioDynamics, Inc.Feb 2026$155.55M USD-9.7%+5.5%59.7%
EOLSEvolus, Inc.Mar 2026$138.92M USD+5.5%+12.3%63.0%
MNPRMonopar Therapeutics Inc.Mar 2026$137.74M USD+150.1%+120.1%99.8%
Peer median (excluding ORGO) —-4.4%+5.1%78.9%

Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents113.93M102.48M104.34M135.57M93.68M
Short-term Investments00000
Net Receivables82.46M89.45M82M109.86M217.45M
Inventory25.02M24.78M28.25M26.22M29.63M
Other Current Assets711K5.1M1.19M5.67M21.43M
Total Current Assets226.98M222.61M225.04M285.94M362.19M
Property, Plant & Equipment (Net)128.3M145.66M156.35M126.24M159.46M
Goodwill28.77M28.77M28.77M28.77M28.77M
Intangible Assets25.67M20.79M15.87M12.47M9.15M
Long-term Investments0015.87M00
Tax Assets31.99M30.01M28M39.46M29.96M
Other Non-current Assets1.54M1.52M(9.88M)5.01M9.2M
Total Non-current Assets216.28M226.75M234.98M211.95M236.54M
Total Assets443.26M449.36M460.03M497.89M598.73M
Account Payables29.34M32.33M30.72M28.91M31.95M
Short-term Debt2.66M4.54M5.49M018.64M
Tax Payables1.16M2.63M2.8M4.29M0
Deferred Revenue00000
Other Current Liabilities29.44M9.33M22.17M25.29M49.53M
Total Current Liabilities82.71M75.02M80.51M77.48M100.12M
Long-term Debt70.77M66.23M60.75M050.71M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.56M1.12M1.21M894K(49.51M)
Total Non-current Liabilities119.22M108.67M100.85M35.09M64.69M
Total Liabilities201.92M183.69M181.36M112.57M164.81M
Common Stock13K13K13K13K13K
Retained Earnings(60.83M)(45.3M)(40.97M)(40.11M)(3.08M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity241.34M265.67M278.66M385.32M433.92M
Total Debt132.3M123.79M119.35M43.31M132.84M
Net Debt18.37M21.31M15.01M(92.26M)39.17M

Organogenesis Holdings Inc.

NASDAQ:ORGO

Intrinsic Alpha fair value

Locked

Current Price

$0.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.